Free Trial

Danaher (DHR) Stock Forecast & Price Target

Danaher logo
$197.08 -0.08 (-0.04%)
Closing price 08/1/2025 03:59 PM Eastern
Extended Trading
$196.02 -1.06 (-0.54%)
As of 08/1/2025 07:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Danaher - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
3
Buy
17

Based on 20 Wall Street analysts who have issued ratings for Danaher in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 20 analysts, 3 have given a hold rating, and 17 have given a buy rating for DHR.

Consensus Price Target

$247.61
25.64% Upside
According to the 20 analysts' twelve-month price targets for Danaher, the average price target is $247.61. The highest price target for DHR is $315.00, while the lowest price target for DHR is $205.00. The average price target represents a forecasted upside of 25.64% from the current price of $197.08.
Get the Latest News and Ratings for DHR and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Danaher and its competitors.

Sign Up

DHR Analyst Ratings Over Time

TypeCurrent Forecast
8/2/24 to 8/2/25
1 Month Ago
7/3/24 to 7/3/25
3 Months Ago
5/4/24 to 5/4/25
1 Year Ago
8/3/23 to 8/2/24
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
17 Buy rating(s)
16 Buy rating(s)
16 Buy rating(s)
12 Buy rating(s)
Hold
3 Hold rating(s)
4 Hold rating(s)
4 Hold rating(s)
5 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$247.61$248.61$248.77$276.88
Forecasted Upside25.64% Upside22.42% Upside24.92% Upside0.05% Upside
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy

DHR Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

DHR Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Danaher Stock vs. The Competition

TypeDanaherMedical CompaniesS&P 500
Consensus Rating Score
2.85
2.81
2.53
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside25.64% Upside10,285.41% Upside14.62% Upside
News Sentiment Rating
Positive News

See Recent DHR News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
7/23/2025UBS Group
3 of 5 stars
Dan Leonard
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetBuy ➝ Buy$240.00 ➝ $225.00+13.61%
7/23/2025Wells Fargo & Company
3 of 5 stars
Brandon Couillard
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetEqual Weight ➝ Equal Weight$210.00 ➝ $205.00+4.31%
7/23/2025Guggenheim
2 of 5 stars
Subbu Nambi
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$250.00+31.55%
7/18/2025Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Catherine Schulte
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOutperform ➝ Outperform$225.00 ➝ $226.00+16.01%
7/11/2025Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Sung Ji Nam
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeSector Perform ➝ Sector Outperform$275.00+33.79%
7/8/2025Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Vijay Kumar
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetOutperform ➝ Outperform$230.00 ➝ $226.00+13.23%
6/24/2025Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
L. Sergott
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$215.00 ➝ $225.00+14.20%
6/5/2025Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$240.00 ➝ $235.00+22.45%
4/25/2025HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$270.00 ➝ $240.00+21.41%
4/23/2025Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform$225.00 ➝ $230.00+17.04%
4/23/2025TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy$240.00 ➝ $248.00+26.20%
4/23/2025Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$260.00 ➝ $240.00+22.13%
4/23/2025Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Conor McNamara
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$250.00 ➝ $250.00+25.71%
4/23/2025The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Sykes
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetNeutral ➝ Neutral$260.00 ➝ $240.00+20.47%
4/22/2025Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Tycho Peterson
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetBuy ➝ Buy$260.00 ➝ $230.00+19.75%
4/22/2025JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Tycho Peterson
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetOverweight ➝ Overweight$280.00 ➝ $260.00+35.37%
4/14/2025Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$265.00 ➝ $230.00+19.16%
4/7/2025Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy
4/7/2025Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform$275.00 ➝ $220.00+21.74%
3/14/2025Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Daniel Arias
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy$260.00+27.48%
2/3/2025Raymond James Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Andrew Cooper
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Market Perform
10/23/2024Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
J. Johnson
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$315.00 ➝ $315.00+23.29%
10/23/2024KeyCorp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$290.00 ➝ $310.00+19.45%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 04:54 AM ET.


Should I Buy Danaher Stock? DHR Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, August 1, 2025. Please send any questions or comments about these Danaher pros and cons to contact@marketbeat.com.

Danaher
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Danaher Co.:

  • Danaher Co. has a strong dividend payout ratio of 27.23%, indicating a commitment to returning value to shareholders through dividends.
  • The current stock price is around $197, which may present a buying opportunity for investors looking for growth potential.
  • Recent analyst ratings show a consensus of "Moderate Buy," with a significant number of analysts assigning buy ratings, suggesting positive market sentiment.
  • Danaher Co. has a diverse portfolio of professional, medical, industrial, and commercial products, which can help mitigate risks associated with market fluctuations.
  • Institutional ownership is high, with 79.05% of the stock held by hedge funds and other institutional investors, indicating confidence in the company's future performance.

Danaher
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Danaher Co. for these reasons:

  • Recent price target adjustments by analysts have shown a downward trend, with some targets being lowered significantly, which may indicate concerns about future performance.
  • Insider selling has occurred, with the Chairman selling a substantial number of shares, which could signal a lack of confidence in the company's short-term prospects.
  • The stock has experienced volatility, with a 12-month high of $279.90 and a low of $171.00, suggesting potential instability in its price movements.
  • Some analysts have issued hold ratings, indicating that not all market participants are convinced of the stock's immediate upside potential.
  • The company's debt-to-equity ratio is relatively low at 0.32, which is generally positive, but it may also indicate limited leverage for growth opportunities compared to competitors with higher ratios.

DHR Forecast - Frequently Asked Questions

According to the research reports of 20 Wall Street equities research analysts, the average twelve-month stock price forecast for Danaher is $247.61, with a high forecast of $315.00 and a low forecast of $205.00.

20 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Danaher in the last twelve months. There are currently 3 hold ratings and 17 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" DHR shares.

According to analysts, Danaher's stock has a predicted upside of 25.64% based on their 12-month stock forecasts.

Over the previous 90 days, Danaher's stock had 1 upgrade by analysts.

Danaher has been rated by research analysts at Barclays, Deutsche Bank Aktiengesellschaft, Evercore ISI, Guggenheim, Robert W. Baird, Scotiabank, UBS Group, and Wells Fargo & Company in the past 90 days.

Analysts like Danaher more than other "medical" companies. The consensus rating score for Danaher is 2.85 while the average consensus rating score for "medical" companies is 2.81. Learn more on how DHR compares to other companies.


This page (NYSE:DHR) was last updated on 8/2/2025 by MarketBeat.com Staff
From Our Partners